Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares, par value US$0.0001 per share
-
Shares outstanding
-
20,679,958
-
Total 13F shares
-
1,322,529
-
Share change
-
+970,359
-
Total reported value
-
$8,138,853
-
Put/Call ratio
-
350%
-
Price per share
-
$6.16
-
Number of holders
-
20
-
Value change
-
+$5,984,886
-
Number of buys
-
6
-
Number of sells
-
7
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares, par value US$0.0001 per share (CASI) as of Q3 2024
As of 30 Sep 2024,
CASI Pharmaceuticals, Inc. - Ordinary Shares, par value US$0.0001 per share (CASI) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,322,529 shares.
The largest 10 holders included
VR Adviser, LLC, Wellington Shields Capital Management, LLC, ADAR1 Capital Management, LLC, Wellington Shields & Co., LLC, RENAISSANCE TECHNOLOGIES LLC, Woodline Partners LP, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, and Royal Bank of Canada.
This page lists
20
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.